Evidence map›Paper›PMID 39394831›Full record

ArticleJournal of cosmetic dermatology2025

Efficacy of Topical Hydroxypinacolone Retinoate-Peptide Product Versus Fractional CO

Lucas Kruger, Kathryn Bambino, Kristine Schmalenberg, Uma Santhanam, David Orentreich, Catherine Orentreich, Jodi Logerfo, Claude Saliou

Abstract readComparative Study
In one paragraph

Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lucas KrugerClinique, New York, New York, USA.
Kathryn BambinoResearch and Development, The Estée Lauder Companies, Melville, New York, USA.
Kristine SchmalenbergClinique, New York, New York, USA.
Uma SanthanamResearch and Development, The Estée Lauder Companies, Melville, New York, USA.
David OrentreichOrentreich Medical Group, New York, New York, USA.
Catherine OrentreichOrentreich Medical Group, New York, New York, USA.
Jodi LogerfoOrentreich Medical Group, New York, New York, USA.
Claude SaliouResearch and Development, The Estée Lauder Companies, Melville, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany people are interested in addressing visible signs of aging with non-invasive cosmetic treatments. Development of effective topical products will provide options to delay or support cosmetic procedures.

aimsThis study assessed and compared the efficacy and tolerance of a topical product used over the course of 16 weeks to a single ablative laser treatment on women with moderate global photodamage on the face.

methodsSubjects in Cell 1 (Laser Cell) were treated over the entire face with a fractional CO

resultsParticipants in the Topical Serum Cell achieved more significant improvement (p < 0.05) in Marionette lines, fine lines (global face), wrinkles (global face), wrinkles (crow's feet), nasolabial folds, texture, smoothness (tactile), global hyperpigmentation, lift, and photodamage compared to participants in the Laser Cell. Participants in the Topical Serum Cell achieved parity in the look of fine lines (crow's feet), forehead lines, glabella, firmness/bounce (tactile), skin tone evenness, radiance.

conclusionsWhile no statistically significant differences in tolerability were observed, treatment with the topical cosmetic product achieved parity or statistically better improvement in parameters compared to laser treatment at 16 weeks.

Indexed as

Cosmetic TechniquesLasers, GasSkin AgingAdministration, CutaneousAdministration, TopicalAdultAgedFaceFemaleHumansMiddle AgedRejuvenationTreatment Outcomeanti‐agingcosmetichydroxypinacolone retinoatelaserphotodamageretinoidwrinkles

Identifiers

PMID39394831
PMCPMC11743323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.